References of "Amory, Hélène"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAtypical myopathy: new insights into the pathophysiology, prevention and management of the condition
Van Galen, Gaby ULg; Serteyn, Didier ULg; Amory, Hélène ULg et al

in Equine Veterinary Education (2008), 20(5), 234-238

Detailed reference viewed: 39 (7 ULg)
Full Text
Peer Reviewed
See detailTetanus in the equine species: a retrospective study of 31 cases.
Van Galen, Gaby ULg; Delguste, Catherine ULg; Sandersen, Charlotte ULg et al

in Tijdschrift voor Diergeneeskunde (2008), 133(12), 512-7

BACKGROUND: Few studies exist about factors affecting the outcome of horses with tetanus. ANIMALS: 31 equids (30 horses and 1 donkey) with a clinical diagnosis of tetanus admitted to the Equine Clinic of ... [more ▼]

BACKGROUND: Few studies exist about factors affecting the outcome of horses with tetanus. ANIMALS: 31 equids (30 horses and 1 donkey) with a clinical diagnosis of tetanus admitted to the Equine Clinic of the University of Liege between 1991 and 2006. The cases were divided into two groups according to the outcome (survivors and non-survivors). METHODS: The clinical data of survivors and non-survivors were compared using an ANOVA (continuous data) or a Fisher's test (discrete data). RESULTS: The survival rate was 32%. Most animals were 5 years or younger, and none had been appropriately vaccinated. The non-survivors were significantly younger than the survivors. The development of dyspnoea, recumbency, and the combination of dysphagia, dyspnoea, and recumbency was observed significantly more in the non-survivors than in the survivors. The timing of tetanus antitoxin administration (either immediately after the onset of suggestive signs or after a delay) was not different between the two groups. The time between the occurrence of a wound and the first signs ranged from 2 days to 2 months and was not significantly different between groups. All non-survivors died within 8 days of the first signs. CONCLUSIONS & CLINICAL IMPORTANCE: This study suggests that young animals are affected more often and more severely by tetanus than older animals. Dyspnoea, recumbency, and the combination of dysphagia, dyspnoea, and recumbency can be considered as indicators of a poor prognosis in equids suffering from tetanus. [less ▲]

Detailed reference viewed: 209 (23 ULg)
Full Text
Peer Reviewed
See detailPharmacological effects of tiludronate in horses after long-term immobilization
Delguste, Catherine ULg; Amory, Hélène ULg; Doucet, Michèle et al

in BONE (2007), 41(3), 414-421

Introduction: Tiludronate, a bisphosphonate, has recently been introduced in veterinary medicine to treat orthopedic conditions in the horse. This study was designed to evaluate its effects on biochemical ... [more ▼]

Introduction: Tiludronate, a bisphosphonate, has recently been introduced in veterinary medicine to treat orthopedic conditions in the horse. This study was designed to evaluate its effects on biochemical biomarkers of bone metabolism and on bone density and structure in an experimental model of disuse osteoporosis induced by cast application in horses. Methods: Two groups of eight horses were immobilized during 8 weeks. The first group (P-group) received a placebo, and the second group (T-group) received tiludronate 1 mg/kg by slow IV infusion. Both treatments were administered twice, 28 days apart. Immobilization consisted of stall rest with the left forelimb packed in a fiberglass cast. It was followed by a 4-week remobilization period and an 8-week standardized training protocol. One biomarker of bone resorption, the C-telopeptides of type 1 collagen cross-links (CTX-1) and one biomarker of bone formation, the bone isoenzyme of alkaline phosphatase (bone ALP), were assessed. Metacarpus III (MCIII) bone mineral density (BMD) and speed of sound (SOS) were evaluated respectively by dual energy X-ray absorptiometry (DEXA) and quantitative ultrasonography (QUS). Lameness was regularly assessed during the remobilization and training periods. Group- and time-related effects were tested by analysis of variance on repeated measurements. Results: A rapid, transient and significant decrease in CTX-1 concentration was seen after each treatment in the T-group only. No significant differences between groups were seen in the evolution of bone ALP activity. At the end of the experiment, the loss of MCIII BMD measured by DEXA in the immobilized limb was significantly less in the T-group than in the P-group. The MCIII SOS measured by QUS did not significantly vary within or between groups throughout the study. Discussion and conclusions: Tiludronate was found to significantly reduce bone resorption during immobilization, as well as to prevent long-term osteopenia in the immobilized limb. Disuse osteopenia did not affect the lateral superficial cortex of MCIII. (C) 2007 Elsevier Inc. All rights reserved. [less ▲]

Detailed reference viewed: 32 (2 ULg)
Peer Reviewed
See detailTetanus in the horse
Van Galen, Gaby ULg; Amory, Hélène ULg

Conference (2007, April 28)

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailPrévenir la myopathie atypique du cheval au pré par la gestion raisonnée des pâtures et des chevaux établie sur base de l'identification des facteurs de risques de la maladie
Votion, Dominique ULg; Delguste, Catherine ULg; Amory, Hélène ULg et al

in 33ème Journée de la Recherche Equine (2007, March 08)

La myopathie atypique (MA) des équidés est un syndrome de destruction musculaire massive et sévère affectant des chevaux séjournant en pâture. Cette myopathie, généralement fatale endéans les 72 heures ... [more ▼]

La myopathie atypique (MA) des équidés est un syndrome de destruction musculaire massive et sévère affectant des chevaux séjournant en pâture. Cette myopathie, généralement fatale endéans les 72 heures, est rencontrée en France de manière significative et récurrente depuis l’automne 2002. La Belgique a reconnu ses premiers cas de MA au cours de l’automne 2000. Grâce à la collecte systématique des données épidémiologiques et cliniques des cas belges confirmés par analyse histologique de muscles prélevés post mortem, il a été possible de définir les facteurs de risques contribuant à l’émergence de la maladie dans une prairie et/ ou au sein d’un élevage. A partir de ces facteurs de risques identifiés, des mesures de prévention de la MA sont proposées et discutées. [less ▲]

Detailed reference viewed: 119 (9 ULg)
Peer Reviewed
See detailThe composition of the inflammatory infiltrate in 3 cases of polyneuritis equi
Van Galen, Gaby ULg; Sandersen, Charlotte ULg; Delguste, Catherine ULg et al

in In Proccedings of the Second congress of the European College od Equine Internal Medicine (ECEIM) (2007, February 02)

Detailed reference viewed: 23 (7 ULg)
Full Text
Peer Reviewed
See detailMorphological alterations in oxidative muscles and mitochondrial structure associated with equine atypical myopathy
Cassart, Dominique ULg; Baise, Etienne ULg; Cherel, Yann et al

in Equine Veterinary Journal (2007), 39(1), 26-32

REASONS FOR PERFORMING STUDY: There is a lack of well documented studies about muscular lesions in equine atypical myopathy (EAM). <br /> <br />OBJECTIVES: To characterise morphopathological changes of ... [more ▼]

REASONS FOR PERFORMING STUDY: There is a lack of well documented studies about muscular lesions in equine atypical myopathy (EAM). <br /> <br />OBJECTIVES: To characterise morphopathological changes of striated muscles and myocardium, to progress understanding of this disease. <br /> <br />METHODS: Thirty-two horses age 0.5-7 years kept on pasture were referred for a sudden ataxia/myoglobinuria syndrome. Clinical examination (stiffness, muscle pain, muscle fasciculations, abnormal gait, recumbency, myoglobinuria, tachycardia, sweating) and plasma CPK, LDH and AST levels were consistent with extensive myonecrosis and, together with anamnestic data, with so-called 'equine atypical myopathy' (EAM), a disease of unknown aetiology reported since 1939. Macroscopic and microscopic (histology, histoenzymology, ultrastructure) lesions were evaluated. <br /> <br />RESULTS: Necropsic examination revealed large areas of muscle necrosis, the extent and severity of which varied between cases and muscles, but which were clearly more constant and severe in respiratory and postural muscles and in the myocardium. Histology highlighted a multifocal and monophasic process compatible with Zenker degeneration/necrosis that mostly and segmentally affected type 1 fibres. Histochemical evaluation revealed a weak and disorganised pattern of NADH tetrazolium reductase staining, the absence of calcium salts precipitates and a dramatic accumulation of lipid droplets. Ultrastructural examination often revealed fibres of which the sole modifications were altered mitochondria and sarcoplasmic lipidosis. <br /> <br />CONCLUSIONS: Taken together, the data suggest that a primary alteration of mitochondria should be considered, although secondary mitochondrial abnormalities have yet to be ruled out. <br /> <br />POTENTIAL RELEVANCE: The morphological features gathered here reveal that EAM shares most of the characteristics of toxic myopathies. [less ▲]

Detailed reference viewed: 244 (23 ULg)
Peer Reviewed
See detailCleft Palate (CP): not only a diagnosis in foals
Van Galen, Gaby ULg; Delguste, Catherine ULg; Verwilghen, Denis ULg et al

Poster (2007, January)

Detailed reference viewed: 24 (8 ULg)
Full Text
See detailLe syndrome Piro-like chez le cheval
Sandersen, Charlotte ULg; Pittel, PH; Amory, Hélène ULg

in Proceedins of the 24th Annual Congress of the Belgian Equine Practitioners Society (BEPS) (2007)

Detailed reference viewed: 42 (1 ULg)
Full Text
See detailLe syndrome Piro-like: diagnostic différentiel sur base des symptômes et cas cliniques de cas de syndrome de piro-like incluant les moyens de diagnostic
Amory, Hélène ULg; Pittel, PH

in Proceedings of the Annual meeting of the French Equine Veterinary Association (AVEF) (2007)

Detailed reference viewed: 27 (2 ULg)
Full Text
See detailComment aborder un cas de fièvre d’origine inconnue
Amory, Hélène ULg

in Proceedings of the Annual meeting of the French Equine Veterinary Association (AVEF) (2007)

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailSymptomatic approach: icterus
Amory, Hélène ULg

in Proceedings of first Belgian International Congress of Equine Veterinarians and farriers (Hippos 2007) (2007)

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailDiagnostic differentiel du syndrome "piro-like" chez les équidés
Sandersen, Charlotte ULg; Amory, Hélène ULg

in Bulletin des Journées Nationales des GTV (2007)

Detailed reference viewed: 33 (2 ULg)
Full Text
Peer Reviewed
See detailApproche cliniques de la fièvre inconnue chez le cheval
Sandersen, Charlotte ULg; Amory, Hélène ULg

in Bulletin des journées nationales des GTV (2007)

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailPharmacologie clinique des bisphosphonates : revue de littérature axée sur le tiludronate chez le cheval.
Delguste, Catherine ULg; Lepage, Olivier M; Amory, Hélène ULg et al

in Annales de Médecine Vétérinaire (2007), 151

Detailed reference viewed: 34 (3 ULg)
Full Text
Peer Reviewed
See detailDiagnostic différentiel des souffles cardiaques en période néonatale chez le poulain
Amory, Hélène ULg

in Nouveau Praticien Vétérinaire Equine (2007)

Detailed reference viewed: 8 (1 ULg)
Peer Reviewed
See detailComparative pharmacokinetics of two intravenous dosage rates of tiludronate in healthy adult horses
Delguste, Catherine ULg; Amory, Hélène ULg; Guyonnet, Jérôme et al

Conference (2007)

Plasma and urine pharmacokinetics of tiludronate administered once daily as an intravenous bolus of 0.1 mg/kg for ten consecutive days (group 1, n=6) was compared to a single slow infusion of 1 mg/kg ... [more ▼]

Plasma and urine pharmacokinetics of tiludronate administered once daily as an intravenous bolus of 0.1 mg/kg for ten consecutive days (group 1, n=6) was compared to a single slow infusion of 1 mg/kg (group 2, n=6) in healthy adult horses. Plasma samples were collected at regular intervals for a period of 16 and 7 days in groups 1 and 2 respectively. Continuous urine collection for determination of cumulative urinary excretion of tiludronate was performed during 16 and 7 days in groups 1 and 2 respectively, and over 24-hour periods every 10 days until 60 days after the last tiludronate administration in both groups. Tiludronate concentrations were obtained in all plasma and urine samples using HPLC with UV detection. Plasma pharmacokinetic parameters were determined using a noncompartmental approach. Group 1 mean (± SD) AUCss was 3.76 (±0.698) mg.h.L-1 and group 2 mean (± SD) AUCtot was 39.07 (±3.699) mg.h.L-1. Mean (± SD) clearance (Cl) was 0.027 (±0.0042) and 0.026 (±0.0022) L.h-1.kg-1 in groups 1 and 2, respectively. Neither the dose corrected AUC (p=0.724) nor the Cl (p=0.528) were statistically different between groups. Relative plasma bioavailability (infusion versus bolus) was 103%. Cumulative urine tiludronic acid excretion could not be compared between groups due to analytical limitations (LOQ of 0.025 mg.L-1), which led to numerous missing data particularly in group 1, and an inability to conduct appropriate statistical and pharmacokinetic analyses. In conclusion, both dosage rates of tiludronate were considered bioequivalent with regards to plasma pharmacokinetics. [less ▲]

Detailed reference viewed: 35 (1 ULg)